Drug intelligence / Profile preview

Insulin-secreting human adipose tissue derived mesenchymal stem cells

Development stage: Preclinical
Lead developer: Hope Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Portal Circulation

Overview

Insulin-secreting human adipose tissue derived mesenchymal stem cells (IS-h-ADMSC) are a type of cell therapy. These cells are mesenchymal stem cells that originate from human adipose tissue and have been engineered to secrete insulin. They are utilized in co-transplantation strategies, often alongside hematopoietic stem cells, to treat conditions such as insulin-dependent diabetes mellitus (IDDM), particularly in the context of polyglandular autoimmune syndrome type 3 (PGAS-3). The therapeutic aim is to provide a sustained source of insulin to help regulate blood glucose levels.

Beyond the preview

Go deeper on Insulin-secreting human adipose tissue derived mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulin-secreting human adipose tissue derived mesenchymal stem cells.

Explore the full profile